Clinical trialNCT04817618RecruitingPhase 3Interventional

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

SponsorNovartis PharmaceuticalsEnrollment98C3G

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

87 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Withdrawn
Novartis Investigative Site
Buenos Aires, Argentina
Completed
Novartis Investigative Site
CABA, Argentina
Withdrawn

Belgium

Novartis Investigative Site
Edegem, Belgium
Withdrawn
Novartis Investigative Site
Leuven, Belgium
Withdrawn

Brazil

Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Active, not recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil
Recruiting
Novartis Investigative Site
Passo Fundo, Rio Grande do Sul, Brazil
Recruiting
Novartis Investigative Site
Joinville, Santa Catarina, Brazil
Withdrawn
Novartis Investigative Site
Santo André, São Paulo, Brazil
Withdrawn
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Withdrawn
Novartis Investigative Site
Salvador, Brazil
Recruiting

Canada

Novartis Investigative Site
London, Ontario, Canada
Completed
Novartis Investigative Site
Toronto, Ontario, Canada
Completed
Novartis Investigative Site
Montreal, Quebec, Canada
Withdrawn

China

Novartis Investigative Site
Guangzhou, Guangdong, China
Active, not recruiting
Novartis Investigative Site
Wuhan, Hubei, China
Withdrawn
Novartis Investigative Site
Beijing, China
Active, not recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Shanghai, China
Active, not recruiting

Czechia

Novartis Investigative Site
Prague, Czechia
Completed

France

Novartis Investigative Site
Lille, France
Completed
Novartis Investigative Site
Marseille, France
Withdrawn
Novartis Investigative Site
Montpellier, France
Withdrawn
Novartis Investigative Site
Paris, France
Withdrawn
Novartis Investigative Site
Paris, France
Completed

Germany

Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Active, not recruiting
Novartis Investigative Site
Aachen, Germany
Withdrawn
Novartis Investigative Site
Erlangen, Germany
Completed
Novartis Investigative Site
Essen, Germany
Completed
Novartis Investigative Site
Hamburg, Germany
Completed
Novartis Investigative Site
Hanover, Germany
Withdrawn
Novartis Investigative Site
Heidelberg, Germany
Active, not recruiting
Novartis Investigative Site
Mainz, Germany
Completed

Greece

Novartis Investigative Site
Athens, Greece
Withdrawn
Novartis Investigative Site
Heraklion Crete., Greece
Completed
Novartis Investigative Site
Thessaloniki, Greece
Withdrawn
Novartis Investigative Site
Thessaloniki, Greece
Completed

India

Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Active, not recruiting

47 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboIptacopan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Jul 2021
Primary completion: 29 Jan 2027
Completion: 29 Jan 2027
Last update posted: 13 Jul 2026
Registered enrollment: 98
Registry id: NCT04817618

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-004589-21

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.